Allogene Therapeutics
Biotechnology ResearchCalifornia, United States201-500 Employees
Allogene Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing allogeneic chimeric antigen receptor T cell products for cancer and autoimmune diseases. The firm aims to deliver readily available cell therapy on demand, with improved reliability and greater scale to reach more patients. It operates within the biotechnology research sector, pursuing an off-the-shelf approach to CAR T therapies. In 2026, the company expanded the pivotal ALPHA3 Phase 2 trial to South Korea and Australia.